FDCC
ASND icon

Foster Dykema Cabot & Co’s Ascendis Pharma A/S ASND Stock Holding History

Foster Dykema Cabot & Co’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22
Closed -$2K – 329
2023
Q2 		$2K Buy
+22
New +$1.92K ﹤0.01% 349

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Foster Dykema Cabot & Co's ASND Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of Ascendis Pharma A/S (ASND) in Q3 2023, closing a stake of 22 shares — an estimated $2K sold.

Foster Dykema Cabot & Co first reported a position in ASND in Q2 2023 and held it in 1 quarter. The position peaked at $2K in Q2 2023. 160 funds tracked by Wall St. Rank hold ASND as of Q3 2023.

  • Foster Dykema Cabot & Co reported no remaining Ascendis Pharma A/S position as of Q3 2023 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 22 Ascendis Pharma A/S shares in Q3 2023, an estimated $2K.
  • Foster Dykema Cabot & Co first reported a position in Ascendis Pharma A/S in Q2 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's Ascendis Pharma A/S position peaked at $2K in Q2 2023.
  • 160 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.